BridgeMD
Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.
EU CTIS ID: 2025-524208-31-00
What this study is testing
To evaluate efficacy and safety of Ra223 in monotherapy or in combination with aromatase inhibitors in patients with symptomatic bone metastases from breast cancer.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients aged =/>18 years
- Histological confirmation of breast cancer
- Patients with predominant bone metastases with at least 2 skeletal metastases identified at baseline bone scan.
- The presence of metastases in soft tissues (skin, subcutaneous tissue, muscle fat, lymph nodes) is permitted;
- Performance Status (PS) < or equal to 2 of Eastern Cooperative Oncology Group (ECOG).
- Absolute neutrophil count ≥1,5 x 109/l
You likely can't join if
- Presence of visceral disease and/or other disease conditions for which treatment with cytotoxic chemotherapy is clinically indicated.
- Presence of carcinomatous lymphangitis
- atients with a history of other cancers, except treated basal cell carcinoma or superficial bladder cancer (Ta and Tis, American Joint Committee on Cancer, 7th edition)
- Previous systemic radiation therapy with strontium-89, samarium-153, rhenium-186, or rhenium-188.
See the full eligibility criteria
- Patients aged =/>18 years
- Histological confirmation of breast cancer
- Patients with predominant bone metastases with at least 2 skeletal metastases identified at baseline bone scan.
- The presence of metastases in soft tissues (skin, subcutaneous tissue, muscle fat, lymph nodes) is permitted;
- Performance Status (PS) < or equal to 2 of Eastern Cooperative Oncology Group (ECOG).
- Absolute neutrophil count ≥1,5 x 109/l
- Platelet count ≥100 x 109/l without platelet transfusion within 4 weeks before the first cycle of Radium-223 dichlorid
- Hemoglobin (Hb) ≥9,0 g/dl (100 g/l) without transfusion or erythropoietin within 4 weeks before the first administration of Radium-223 dichloride.
- Presence of visceral disease and/or other disease conditions for which treatment with cytotoxic chemotherapy is clinically indicated.
- Presence of carcinomatous lymphangitis
- atients with a history of other cancers, except treated basal cell carcinoma or superficial bladder cancer (Ta and Tis, American Joint Committee on Cancer, 7th edition)
- Previous systemic radiation therapy with strontium-89, samarium-153, rhenium-186, or rhenium-188.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.